کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5685405 | 1598223 | 2017 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ombitasvirparitaprevirend-stage renal disease (ESRD) - بیماری کلیوی مرحله پایانی (ESRD)direct-acting antivirals - داروهای ضد ویروسی مستقیمdasabuvir - داسابووریRibavirin - ریباویرین Ritonavir - ریتونویرCirrhosis - سیروزadverse event - عارضه جانبی یا عوارض جانبیHemodialysis - همودیالیزHepatitis C virus (HCV) - ویروس هپاتیت C (HCV)sustained virological response - پاسخ ویروسی بالقوهHCV genotype - ژنوتیپ HCVdecreased kidney function - کاهش عملکرد کلیهCase reports - گزارش موارد
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای کلیوی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks. Clinical and virologic assessment was performed every 4 weeks during the treatment and at posttreatment weeks 4 and 12. All patients achieved a sustained virologic response at posttreatment week 12. 80% of patients reported at least one adverse event: fatigue and anemia of mild intensity were the most common; a single episode of moderate liver decompensation was observed. The paritaprevir/ritonavir/ombitasvir/dasabuvir antiviral regimen is effective and well tolerated in genotype 1 or 4 hepatitis C virus-infected patients on hemodialysis therapy with compensated cirrhosis and/or failure of previous treatments.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: American Journal of Kidney Diseases - Volume 70, Issue 2, August 2017, Pages 297-300
Journal: American Journal of Kidney Diseases - Volume 70, Issue 2, August 2017, Pages 297-300
نویسندگان
Francesca Romana MD, Massimo MD, Raffaella MD, Caterina MD, Laura MD, Gianpiero MD, Antonio PhD, Maurizio PhD,